MedPath
Found 4 clinical trials|View Analysis
Sort by:

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Phase 1
Completed
Conditions
Physiological Effects of Drugs
Psychotic Disorders
Tranquilizing Agents
Schizophrenia
Mood Disorders
Mental Disorders
Antipsychotic Agents
Schizophrenia Spectrum and Other Psychotic Disorders
Central Nervous System Depression
Neurotransmitter Agents
Interventions
Drug: LY03010 156 mg treatment group, gluteal
Drug: LY03010 156 mg treatment group, deltoid
Drug: LY03010 351 mg treatment group, deltoid
Drug: LY03010 351 mg treatment group, gluteal
First Posted Date
2022-04-11
Last Posted Date
2024-03-19
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
89
Registration Number
NCT05321602
Locations
🇺🇸

Woodland International Research Group, Little Rock, Arkansas, United States

🇺🇸

CNS Research, Garden Grove, California, United States

🇺🇸

NRC Research Institute, Orange, California, United States

and more 6 locations

Relative Bioavailability of LY03010 Compared to Listed Drug

Phase 1
Completed
Conditions
Schizophrenia Spectrum
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Schizophrenia
Psychotic Disorders
Mood Disorders
Interventions
First Posted Date
2021-06-10
Last Posted Date
2023-04-25
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
281
Registration Number
NCT04922593
Locations
🇺🇸

Uptown Research Institute, LLC, Chicago, Illinois, United States

🇺🇸

Innovative Clinical Research, Inc., Miami Lakes, Florida, United States

🇺🇸

Collaborative Neuroscience Network, Inc., Garden Grove, California, United States

and more 5 locations

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Phase 1
Completed
Conditions
Schizophrenia Patients
Interventions
First Posted Date
2020-10-01
Last Posted Date
2020-11-09
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
36
Registration Number
NCT04572685
Locations
🇺🇸

Hassman Research Institute, Berlin, New Jersey, United States

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Phase 1
Completed
Conditions
Schizoaffective Disorder
Schizo Affective Disorder
Schizophrenia
Interventions
First Posted Date
2018-11-23
Last Posted Date
2019-08-13
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
48
Registration Number
NCT03751488
Locations
🇺🇸

Collaborative Neuroscience Network LLC, Garden Grove, California, United States

🇺🇸

Hassman Research Institute, Berlin, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath